Literature DB >> 28464369

Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.

S Sookoian1,2, C J Pirola1,3.   

Abstract

BACKGROUND: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is closely associated with the co-occurrence of multiple pathological conditions characterising the metabolic syndrome (MetS), obesity in particular. However, NAFLD also develops in lean subjects, whose risk factors remain poorly defined.
METHODS: We performed a meta-analysis of 15 studies, along with the data pertaining to our own population (n=336 patients). Data from lean (n=1966) and obese (n=5938) patients with NAFLD were analysed; lean (n=9946) and obese (n=6027) subjects without NAFLD served as controls.
RESULTS: Relative to the lean non-NAFLD controls, lean patients with NAFLD were older (3.79±0.72 years, P=1.36×10-6 ) and exhibited the entire spectrum of the MetS risk factors. Specifically, they had a significant (P=10-10 ) increase in plasma glucose levels (6.44±1.12 mg/dL) and HOMA-IR (0.52±0.094-unit increment), blood lipids (triglycerides: 48.37±3.6, P=10-10 and total cholesterol: 7.04±3.8, mg/dL, P=4.2×10-7 ), systolic (5.64±0.7) and diastolic (3.37±0.9) blood pressure (mm Hg), P=10-10 , and waist circumference (5.88±0.4 cm, P=10-10 ); values denote difference in means±SE. Nevertheless, the overall alterations in the obese group were much more severe when compared to lean subjects, regardless of the presence of NAFLD. Meta-regression suggested that NAFLD is a modifier of the level of blood lipids.
CONCLUSION: Lean and obese patients with NAFLD share a common altered metabolic and cardiovascular profile. The former, while having normal body weight, showed excess of abdominal adipose tissue as well as other MetS features.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28464369     DOI: 10.1111/apt.14112

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  47 in total

1.  Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease.

Authors:  Luigi Elio Adinolfi; Aldo Marrone; Luca Rinaldi
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

2.  Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.

Authors:  Yusuf Yılmaz; Haluk Tarık Kanı; Coşkun Özer Demirtaş; Eda Kaya; Aybüke Fatma Sapmaz; Lubna Qutranji; Tasnim Alkayyali; Kerim Deniz Batun; Mahmut Batman; Berk Toy; Aslı Çiftaslan
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

3.  The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  J Physiol Biochem       Date:  2022-05-12       Impact factor: 4.158

4.  Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach.

Authors:  Liang Dai; Jingjuan Xu; Baocheng Liu; Yanqi Dang; Ruirui Wang; Lijie Zhuang; Dong Li; Lulu Jiao; Jianying Wang; Lei Zhang; Linda L D Zhong; Wenjun Zhou; Guang Ji
Journal:  Front Med       Date:  2022-04-26       Impact factor: 4.592

5.  The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study.

Authors:  Ping-Fang Hu; Xin Zeng; Zi-Yuan Zou; Wei Tang; Yi-Bin Guo; Zong-Li Yuan; Pei-Mei Shi; Yu Tan; Yan Song; Yong-Quan Shi; Wei-Fen Xie
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

6.  Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance.

Authors:  Liufeng Mao; Lijie Peng; Xiaomei Ren; Yi Chu; Tao Nie; Wanhua Lin; Xuemei Zhao; Andrew Libby; Yong Xu; Yu Chang; Chong Lei; Kerry Loomes; Na Wang; Jinsong Liu; Moshe Levi; Donghai Wu; Xiaoyan Hui; Ke Ding
Journal:  ACS Bio Med Chem Au       Date:  2022-01-31

Review 7.  Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals.

Authors:  Meaghan Phipps; Julia Wattacheril
Journal:  Frontline Gastroenterol       Date:  2019-12-13

8.  The association of non-alcoholic fatty liver disease and cardiac structure and function-Framingham Heart Study.

Authors:  Laura S Chiu; Alison Pedley; Joseph M Massaro; Emelia J Benjamin; Gary F Mitchell; David D McManus; Jayashri Aragam; Ramachandran S Vasan; Susan Cheng; Michelle T Long
Journal:  Liver Int       Date:  2020-07-25       Impact factor: 5.828

Review 9.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

10.  Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study.

Authors:  Yasir Mohammed Khayyat
Journal:  Physiol Rep       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.